We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+23.32%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.26B
AUM Growth
+$63.8M
(+5.3%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-12.49%
Top 10 Holdings %
Top 10 Hldgs %
50.84%
Holding
38
New
4
Increased
5
Reduced
16
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$47.5M |
| 2 |
Zimmer Biomet
ZBH
|
+$25.2M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$8.61M |
| 4 |
Enphase Energy
ENPH
|
+$5.51M |
| 5 |
Nektar Therapeutics
NKTR
|
+$4.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FDC
First Data Corporation
FDC
|
+$45M |
| 2 |
CZR
Caesars Entertainment Corporation
CZR
|
+$26.7M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$19.5M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$18.8M |
| 5 |
Atara Biotherapeutics
ATRA
|
+$16.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.66% |
| 2 | Technology | 15.81% |
| 3 | Consumer Discretionary | 10.65% |
| 4 | Communication Services | 7.54% |
| 5 | Consumer Staples | 5.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
GoDaddy
GDDY
$10.5B
| $79.5M | 6.29% |
1,056,900
-50,000
| -5% | -$3.52M |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $79.4M | 6.29% |
2,841,761
-218,910
| -7% | -$5.16M |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $69.9M | 5.54% |
4,773,718
| – | – |
|
|
4
Atara Biotherapeutics
ATRA
$74.4M
| $69.7M | 5.51% |
70,108
-18,169
| -21% | -$16.9M |
|
5
Post Holdings
POST
$4.15B
| $65.5M | 5.19% |
915,185
-169,383
| -16% | -$11.1M |
|
6
Charter Communications
CHTR
$17.4B
| $59.5M | 4.71% |
171,451
| – | – |
|
7
Alnylam Pharmaceuticals
ALNY
$27.1B
| $58.2M | 4.6% |
622,450
-36,335
| -6% | -$3.04M |
|
8
Ironwood Pharmaceuticals
IRWD
$688M
| $56.6M | 4.48% |
4,993,179
| – | – |
|
9
Morgan Stanley
MS
$332B
| $53.4M | 4.22% |
1,264,488
-98,819
| -7% | -$4.16M |
|
|
10
Labcorp
LH
$25.5B
| $50.6M | 4.01% |
+385,364
| New | +$47.5M |
|
11
Heron Therapeutics
HRTX
$94.4M
| $49.8M | 3.94% |
2,036,199
-446,110
| -18% | -$11.7M |
|
12
MGM Resorts International
MGM
$11.4B
| $45.4M | 3.59% |
1,768,829
-217,860
| -11% | -$5.98M |
|
|
WMGI
13
DELISTED
Wright Medical Group Inc
WMGI
| $44.8M | 3.55% |
1,424,239
| – | – |
|
|
14
Nektar Therapeutics
NKTR
$2.38B
| $41.6M | 3.29% |
82,566
+6,938
| +9% | +$4.11M |
|
15
GDS Holdings
GDS
$6.49B
| $39.5M | 3.12% |
1,105,720
-283,794
| -20% | -$8.59M |
|
16
Viasat
VSAT
$10.6B
| $37.2M | 2.95% |
480,179
-90,800
| -16% | -$6.32M |
|
17
VeriSign
VRSN
$26.1B
| $36.8M | 2.92% |
202,960
-87,883
| -30% | -$15.1M |
|
18
Liberty Broadband Class A
LBRDA
$4.9B
| $35.8M | 2.83% |
390,292
| – | – |
|
19
Caesars Entertainment
CZR
$6.06B
| $34.9M | 2.76% |
746,498
-366,338
| -33% | -$16.7M |
|
20
TG Therapeutics
TGTX
$8B
| $32.2M | 2.55% |
4,003,481
+211,950
| +6% | +$1.15M |
|
21
Shake Shack
SHAK
$2.54B
| $30.6M | 2.43% |
518,181
+61,258
| +13% | +$3.14M |
|
|
22
Zimmer Biomet
ZBH
$18.1B
| $27.5M | 2.18% |
+222,062
| New | +$25.2M |
|
23
Rocket Pharmaceuticals
RCKT
$337M
| $26.8M | 2.12% |
1,529,032
-223,870
| -13% | -$3.53M |
|
24
Teva Pharmaceuticals
TEVA
$40.9B
| $23.5M | 1.86% |
1,500,000
| – | – |
|
25
Centene
CNC
$30.7B
| $19.7M | 1.56% |
371,783
+50,565
| +16% | +$3.07M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q1 2019 Portfolio in Review
As of Q1 2019, Bridger Management held 38 positions worth $1.26B, up 5.3% from $1.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Bridger Management withdrew a net $158M in Q1 2019, closing 5 positions and reducing 16 holdings. Its most notable exit was First Data Corporation, an estimated $45M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Bridger Management opened a new position in Labcorp worth $50.6M.
- Bridger Management's largest Q1 2019 buy was Labcorp: 385,364 shares worth $50.6M.
- Bridger Management added most to Nektar Therapeutics in Q1 2019, an estimated $4.11M increase.
- Bridger Management's biggest Q1 2019 reduction was Caesars Entertainment Corporation, cutting an estimated $26.7M.
- Bridger Management fully exited First Data Corporation in Q1 2019, selling an estimated $45M.
- Bridger Management's ten largest holdings make up 51% of its $1.26B portfolio in Q1 2019.
- Bridger Management opened 4 new positions and closed 5 in Q1 2019.
- Bridger Management's portfolio value rose 5.3% quarter-over-quarter to $1.26B.
Based on Bridger Management's 13F filing for Q1 2019, filed 15 May 2019.